MedCity News November 9, 2021
Elise Reuter

The company started with genetic testing, but expanded to Covid-19 tests and vaccines during the pandemic. It’s valuation has tripled since it last raised a funding round valuing it at $1.5 billion in January.

Color recently raised $100 million in equity, tripling its valuation since it closed a funding round in January. It’s now valued at $4.6 billion.

Kindred Ventures and funds advised by T. Rowe Price Associates led its series E round.

Color, which had started as a genetic testing business in 2015, found a broader use for its infrastructure during the pandemic. The company grew quickly, operating thousands of Covid-19 testing sites, and is now looking at broader public health partnerships.

Before the pandemic, Color started working with...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Healthcare System, Investments, Pharma / Biotech, Precision Medicine, Public Health / COVID, Trends
Transforming public health: a physician’s innovative approach [PODCAST]
Trump Nominates Physicians for CDC Director, Surgeon General
5 Things You Should Know About Long COVID
Q&A: How school eligibility influences the spread of infectious diseases
The surprising effect COVID-19 could have on cancer

Share This Article